Macular degeneration
Conditions
Interventions
Xanmax 2002 lutein supplement
FloraGLO lutein supplement
Sponsors
Seirei Hamamatsu General Hospital (Shizuoka Prefecture)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: No serious eye diseases Visual acuity of 0.8 and more Myopia of less than -6.0 D No gastrointestinal disorders such as malabsorption syndrome and history of gastrectomy causing absorption deficiency No diabetes mellitus No use of lutein and zeaxanthin supplements Non-smoker or no tobacco smoking within the past 1 year Providing informed consent with sufficient understanding of the present study Judged by the investigator to be eligible as a subject on the basis of screening tests Not allergic to lutein or zeaxanthin
Exclusion criteria
Exclusion criteria: Presence of cataract of a severity sufficient to affect the measurement of macular pigment Pupil size less than 6.5 mm Judged by the investigator to be ineligible for other reasons
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Macular pigment optical density | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Change in far and near visual acuity 2.Change in contrast sensitivity and glare-recovery testing 3.Change in response of macular electroretinogram 4.Change in plasma lutein concentration | — |
Countries
Japan
Contacts
Public ContactMasahiro Asano
Seirei Hamamatsu General Hospital (Shizuoka Prefecture) General Clinical Research Center
Outcome results
None listed